Corcept Therapeutics (NASDAQ:CORT – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research report issued on Wednesday, Benzinga reports. They presently have a $40.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective would indicate a potential upside of 28.16% from the stock’s current […]